Login to Your Account

No red 'Heron' as Sustol proves 'MAGIC' in phase III

By Marie Powers
Staff Writer

Friday, May 29, 2015
Investors in Heron Therapeutics Inc. received the good news they were awaiting when the phase III MAGIC study of Sustol (granisetron injection, extended release) hit its primary endpoint.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription